PEGN.jpg
PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
May 14, 2024 16:02 ET | PepGen Inc.
– CONNECT1-EDO51 trial preliminary data from 5mg/kg dose cohort expected mid-2024 – – FREEDOM1-DM1 trial preliminary data from at least 5mg/kg dose cohort expected second half 2024 – – Net...
BioCardia-Final-Logo-2016-JPEG.jpg
BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
May 14, 2024 16:02 ET | BioCardia, Inc.
SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
Ardelyx-Logo-RGB.png
Ardelyx, Inc. Reports Employment Inducement Grants
May 14, 2024 16:02 ET | Ardelyx, Inc.
WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
Biostem main logo .png
BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million
May 14, 2024 16:01 ET | Biostem Technologies
BioStem Technologies Reports Record First Quarter Revenue of $41.9 Million
ProMIS.jpg
ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights
May 14, 2024 16:01 ET | ProMIS Neurosciences Inc.
CAMBRIDGE, Massachusetts and TORONTO, Ontario, May 14, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and...
cswc_logo.png
Capital Southwest Announces Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2024 and Announces Total Dividends of $0.63 per share for the Quarter Ending June 30, 2024
May 14, 2024 16:01 ET | Capital Southwest Corporation
DALLAS, May 14, 2024 (GLOBE NEWSWIRE) -- Capital Southwest Corporation (“Capital Southwest,” “CSWC” or the “Company”) (Nasdaq: CSWC), an internally managed business development company focused on...
scPharmaceuticals_Logo_4C_NEW.jpg
scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:01 ET | scPharmaceuticals, Inc.
Generated 1Q 2024 net FUROSCIX® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents...
logo.png
American Shared Hospital Services Reports First Quarter 2024 Financial Results
May 14, 2024 16:01 ET | American Shared Hospital Services
American Shared Hospital Services Reports First Quarter 2024 Financial Results
Picture1.jpg
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024 16:01 ET | Taysha Gene Therapies, Inc.
Completed dosing in cohort one (low dose, 5.7x1014 total vg) of REVEAL Phase 1/2 adolescent and adult trial with longer-term data supporting the safety profile and durable response of TSHA-102;...